GSK to settle 80,000 Zantac cases for up to $2.2 billion
By Ashleigh Furlong and Jef Feeley | Bloomberg GSK Plc said it will pay as much as $2.2 billion to resolve about 80,000 US court cases related to allegations that its old reflux medication Zantac was contaminated with a suspected carcinogen. The cases represent about 93% of those against the company involving Zantac, GSK said…